Study of Durvalumab (MEDI4736) After Chemo-Radiation for Microsatellite Stable Stage II-IV Rectal Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

May 14, 2018

Primary Completion Date

February 22, 2021

Study Completion Date

December 30, 2021

Conditions
Rectal Cancer
Interventions
DRUG

durvalumab

Within 3-7 days after completion of chemoradiation, patients will receive durvalumab (750 mg IV infusion) every 2 weeks for 4 doses on Day 1(Dose 1), Day 15 (Dose 2), Day 29 (Dose 3), and Day 43 (Dose 4)

Trial Locations (43)

15025

AHN Cancer Institute at Jefferson, Jefferson Hills

15102

UPMC Hillman Cancer at Upper St Clair, Bethel Park

15146

Forbes Regional Hospital, Monroeville

UPMC Hillman Cancer Center at Monroeville, Monroeville

15212

Allegheny General Hospital, Pittsburgh

WPAON/Medical Center Clinic, Pittsburgh

15224

Western Pennsylvania Hospital dba West Penn Hospital, Pittsburgh

15232

UPCI Hillman/Shadyside, Pittsburgh

UPMC Hillman Cancer Center, Pittsburgh

15237

UPMC Cancer Center at Passavant OHA, Pittsburgh

UPMC Hillman Cancer Center at Passvant HOA, Pittsburgh

15301

UPMC Hillman Cancer Center at Washington, Washington

15601

UPMC Hillman Cancer Center at Mt. View, Greensburg

26506

West Virginia University Medicine, Morgantown

West Virginia University, Morgantown

27157

Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem

Wake Forest Medical Center, Winston-Salem

32610

University of Florida, Gainesville

43015

Columbus Oncology and Hematology Associates, Inc., Delaware

Delaware Health Center Grady Cancer Center, Delaware

43050

Knox Community Hospital, Mount Vernon

43055

Licking Memorial Hospital, Newark

43215

Columbus NCORP, Columbus

Grant Medical Center, Columbus

43228

Doctors Hospital, Columbus

43302

Marion General Hospital, Marion

The Mark H. Sangmeister Center, Marion

43701

Genesis Health Care Center, Zanesville

45601

Adena Regional Medical Center, Chillicothe

45662

Southern Ohio Medical Center, Port Clinton

45714

Strecker Cancer Center, Belpre

45750

Marietta Memorial Hospital, Marietta

48109

University of Michigan Oncology, Ann Arbor

University of Michigan, Ann Arbor

62226

Cancer Care Specialists of Central Illinois-Swansea, Swansea

62401

Cancer Care Specialists of Central Illinois-Crossroads Cancer Center, Effingham

62526

Cancer Care Specialists of Central Illinois, Decatur

06437

Smilow Cancer Hospital Care Center at Guilford, Guilford

06510

Smilow Cancer Hospital Care Center at Yale, New Haven

06520

Yale University, Yale Cancer Center, New Haven

06473

Smilow Cancer Hospital Care Center at North Haven, North Haven

06477

Smilow Cancer Hospital Care Center at Trumbull, Trumbull

06385

Smilow Cancer Hospital at Lawrence + Memorial Cancer Center, Waterford

All Listed Sponsors
lead

NSABP Foundation Inc

NETWORK

NCT03102047 - Study of Durvalumab (MEDI4736) After Chemo-Radiation for Microsatellite Stable Stage II-IV Rectal Cancer | Biotech Hunter | Biotech Hunter